leadf
logo-loader
viewTiziana Life Sciences PLC

Tiziana Life Sciences hails key US patent approval that provides added protection for COVID-19 drug

Protection has been granted around the “methods and use” anti-IL 6 and IL-6 receptor monoclonal antibodies for both protective (prophylactic) and therapeutic use

Tiziana Life Sciences PLC -

Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) has received a US patent for its TZLS-501 antibody technology being developed to treat the life-threatening effects of the coronavirus (COVID-19).

Protection has been granted around the “methods and use” of anti-IL 6 and IL-6 receptor monoclonal antibodies for both protective (prophylactic) and therapeutic use.

WATCH: Tiziana Life Sciences recieves US patent for Covid-19 treatment

The grant of this additional patent on TZLS-501 is of “particular significance” for the potential treatment of COVID-19 and other pulmonary diseases such as acute respiratory distress syndrome, the company said.

In the case of COVID, the treatment offers the promise of providing immediate respite if the drug is inhaled directly using a handheld nebuliser.

“The granting of this patent along with our previously filed patent application on inhalation delivery of anti-IL-6 mAbs strengthens our intellectual property for the treatment of lung diseases,” Tiziana chief executive, Dr Kunwar Shailubhai said in a statement.

He added that the company is “expediting” the clinical development of TZLS-501. So, work is ongoing to scale-up manufacturing, develop the inhalation delivery system and to safety test it.

Completion of these studies will enable Tiziana to file an investigational new drug application and initiate a clinical trial in COVID-19 patients by the first quarter of next year, said Shailubhai.

“Subsequently, we plan to use TZLS-501 with the same inhalation delivery technology for the treatment of patients with acute respiratory distress syndrome,” he added.

Quick facts: Tiziana Life Sciences PLC

Price: 139.9 GBX

AIM:TILS
Market: AIM
Market Cap: £267.43 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Tiziana Life Sciences: Delivery method & data 'looks promising' ahead of...

Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) has announced plans to begin a clinical study of its nasally administered Foralumab in COVID-19 patients in Brazil. Proactive analyst Emma Ulker talks to Katie Pilbeam about the trial which will begin shortly with clinical data potentially...

5 hours, 54 minutes ago

2 min read